Comparative Pharmacology
Head-to-head clinical analysis: AVELOX versus VIGAMOX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AVELOX versus VIGAMOX.
AVELOX vs VIGAMOX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Moxifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, thereby interfering with bacterial DNA replication, transcription, repair, and recombination.
Fluoroquinolone antibiotic that inhibits DNA gyrase and topoisomerase IV, preventing bacterial DNA replication.
400 mg orally or intravenously once daily for 7 to 14 days depending on infection severity.
1 drop in affected eye(s) every 4 hours while awake for 7 days; may increase to 1 drop every 2 hours on day 1.
None Documented
None Documented
Terminal elimination half-life is approximately 12 hours (range 10-14 hours) in healthy adults, allowing once-daily dosing. May be prolonged in patients with renal impairment.
Terminal elimination half-life: 12-14 hours; clinically relevant for once-daily dosing
Renal (approximately 45-60% as unchanged drug and metabolites) and biliary/fecal (approximately 20-30% as unchanged drug and metabolites). Total recovery in urine and feces accounts for >96% of the dose.
Renal: 70-80% unchanged; biliary/fecal: 15-20%
Category C
Category C
Antibiotic (Fluoroquinolone)
Antibiotic (Fluoroquinolone)